Dr. Golding is a physician by training with investment experience in both the private and public markets. He currently manages the healthcare/life sciences portfolio for a large family office. Previously, he worked at Consonance Capital, a healthcare-only long/short public equity fund specializing in biopharmaceuticals, medical devices, diagnostics, and healthcare IT. Prior to joining Consonance, Dr. Golding worked in venture capital investing at F-Prime Capital Partners (formerly known as Fidelity Biosciences), a global venture capital firm specializing in biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services/IT. While at F-Prime, Dr. Golding was a Board Observer for Iora Health, an IT-enabled healthcare services company focused on building and operating de novo primary care practices. He was also a Board Observer for Symbiomix Therapeutics, a company focused on developing therapeutics in the area of women’s health (acquired by Lupin). Dr. Golding completed his training in Internal Medicine at Beth Israel Deaconess Medical Center, an affiliate of Harvard Medical School. He gained insight into the area of pharmaceutical regulation through an internship at the Food and Drug Administration in the Office of Regulatory Policy. He holds an MD from the Yale School of Medicine and an MBA from the Yale School of Management. He received a BA from the University of Pennsylvania, where he graduated summa cum laude.